Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.23
HBIO's Cash to Debt is ranked lower than
82% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.56 vs. HBIO: 0.23 )
Ranked among companies with meaningful Cash to Debt only.
HBIO' s Cash to Debt Range Over the Past 10 Years
Min: 0.23  Med: 1.39 Max: N/A
Current: 0.23
Equity to Asset 0.67
HBIO's Equity to Asset is ranked higher than
64% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. HBIO: 0.67 )
Ranked among companies with meaningful Equity to Asset only.
HBIO' s Equity to Asset Range Over the Past 10 Years
Min: 0.65  Med: 0.76 Max: 0.93
Current: 0.67
0.65
0.93
F-Score: 6
Z-Score: 1.42
M-Score: -3.49
WACC vs ROIC
8.55%
4.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -1.61
HBIO's Operating margin (%) is ranked lower than
61% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.16 vs. HBIO: -1.61 )
Ranked among companies with meaningful Operating margin (%) only.
HBIO' s Operating margin (%) Range Over the Past 10 Years
Min: -1.61  Med: 8.56 Max: 11.43
Current: -1.61
-1.61
11.43
Net-margin (%) -18.04
HBIO's Net-margin (%) is ranked lower than
70% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.53 vs. HBIO: -18.04 )
Ranked among companies with meaningful Net-margin (%) only.
HBIO' s Net-margin (%) Range Over the Past 10 Years
Min: -18.04  Med: 2.02 Max: 17.58
Current: -18.04
-18.04
17.58
ROE (%) -22.93
HBIO's ROE (%) is ranked lower than
72% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.19 vs. HBIO: -22.93 )
Ranked among companies with meaningful ROE (%) only.
HBIO' s ROE (%) Range Over the Past 10 Years
Min: -22.93  Med: 2.38 Max: 22.98
Current: -22.93
-22.93
22.98
ROA (%) -15.49
HBIO's ROA (%) is ranked lower than
69% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. HBIO: -15.49 )
Ranked among companies with meaningful ROA (%) only.
HBIO' s ROA (%) Range Over the Past 10 Years
Min: -15.49  Med: 1.78 Max: 16.39
Current: -15.49
-15.49
16.39
ROC (Joel Greenblatt) (%) -5.06
HBIO's ROC (Joel Greenblatt) (%) is ranked lower than
62% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.92 vs. HBIO: -5.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HBIO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -8.13  Med: 24.15 Max: 43.82
Current: -5.06
-8.13
43.82
Revenue Growth (3Y)(%) -4.60
HBIO's Revenue Growth (3Y)(%) is ranked lower than
74% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. HBIO: -4.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HBIO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -23.7  Med: 1.8 Max: 11.5
Current: -4.6
-23.7
11.5
EBITDA Growth (3Y)(%) -48.10
HBIO's EBITDA Growth (3Y)(%) is ranked lower than
98% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. HBIO: -48.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HBIO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.1  Med: -3.4 Max: 29
Current: -48.1
-48.1
29
» HBIO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

HBIO Guru Trades in Q3 2015

Chuck Royce 1,321,600 sh (+0.11%)
Jim Simons 601,100 sh (-3.82%)
» More
Q4 2015

HBIO Guru Trades in Q4 2015

Chuck Royce 1,321,000 sh (-0.05%)
Jim Simons 566,800 sh (-5.71%)
» More
Q1 2016

HBIO Guru Trades in Q1 2016

Chuck Royce 1,546,000 sh (+17.03%)
Jim Simons 557,500 sh (-1.64%)
» More
Q2 2016

HBIO Guru Trades in Q2 2016

Chuck Royce 1,546,000 sh (unchged)
Jim Simons 534,200 sh (-4.18%)
» More
» Details

Insider Trades

Latest Guru Trades with HBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:OTCPK:TDMMF, NAS:BIOL, NAS:PLSE, AMEX:BVX, AMEX:RVP, NAS:HNSN, NAS:LAKE, NAS:ATEC, AMEX:INFU, NAS:EKSO, NAS:DSCI, AMEX:MLSS, NAS:LENS, OTCPK:PSDLF, OTCPK:TSNLF, NAS:SIEN, NAS:CASM, AMEX:ISR, AMEX:DXR, NAS:BLFS » details
Traded in other countries:HBI.Germany,
Harvard Bioscience Inc is a developer, manufacturer and marketer of scientific instruments, systems and lab consumables used to advance life science for basic research, drug discovery, clinical and environmental testing.

Harvard Bioscience Inc is a Delaware corporation, which began its business in 1901. The Company developer, manufacturer and marketer of scientific instruments, systems and lab consumables used to advance life science for basic research, drug discovery, clinical and environmental testing. It has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada, and China. The Company sells its products to researchers in over 100 countries through its sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, GE Healthcare, and other specialized distributors. The Company core product range is organized into five product families: Fluidics, Lab Equipment and Supplies, Molecular Analysis, Cell Physiology, and Animal Physiology. It primarily sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI, and CMA Microdialysis. The Fluidics product family includes Company's traditional syringe pump and peristaltic pump product lines. The products are used in many life science and industrial applications that require accurately controlled fluid dispensing, including infusion, perfusion, cellular microinjection, microfluidics, mass spectrometry calibration, electrospinning and microdialysis. The primary brands are Harvard Apparatus, Harvard Pumps, and KD Scientific. The Lab Equipment and Supplies product family includes products for molecular biology labs with a liquid handling focus. It consists of pipettes and pipette tips, gloves, gel electrophoresis equipment and reagents, autoradiography films, thermal cycler accessories and reagents, sample preparation columns, tissue culture products, and general lab equipment and consumables. Its brands include Denville Scientific, AHN, and others. The Molecular Analysis product family includes spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments. The Company sells spectrophotometers under the names Libra, WPA and BioDrop. The Cell Physiology product family consists of electrophysiology products. The Animal Physiology product family includes instruments and accessories for tissue, organ and animal based lab research, including surgical products, infusion systems, microdialysis instruments, behavior research systems, isolated organ and tissue bath systems, bioreactors for regenerative medicine research, and in vivo electrophysiology recording and stimulation systems. Its product offerings are marketed through Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, InBreath Bioreactor, MCS and TBSI brands and entities. The Company competes with several companies that provides instruments for life science research including, Lonza Group Ltd., Becton Dickinson

Ratios

vs
industry
vs
history
Forward P/E 14.41
HBIO's Forward P/E is ranked higher than
95% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.70 vs. HBIO: 14.41 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.29
HBIO's P/B is ranked higher than
81% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. HBIO: 1.29 )
Ranked among companies with meaningful P/B only.
HBIO' s P/B Range Over the Past 10 Years
Min: 0.62  Med: 1.25 Max: 2.41
Current: 1.29
0.62
2.41
P/S 0.91
HBIO's P/S is ranked higher than
81% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. HBIO: 0.91 )
Ranked among companies with meaningful P/S only.
HBIO' s P/S Range Over the Past 10 Years
Min: 0.51  Med: 1.13 Max: 2.01
Current: 0.91
0.51
2.01
PFCF 480.00
HBIO's PFCF is ranked lower than
98% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.58 vs. HBIO: 480.00 )
Ranked among companies with meaningful PFCF only.
HBIO' s PFCF Range Over the Past 10 Years
Min: 4.94  Med: 15.85 Max: 6590
Current: 480
4.94
6590
POCF 49.66
HBIO's POCF is ranked lower than
90% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.69 vs. HBIO: 49.66 )
Ranked among companies with meaningful POCF only.
HBIO' s POCF Range Over the Past 10 Years
Min: 4.6  Med: 13.75 Max: 647.14
Current: 49.66
4.6
647.14
EV-to-EBITDA 42.22
HBIO's EV-to-EBITDA is ranked lower than
83% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.23 vs. HBIO: 42.22 )
Ranked among companies with meaningful EV-to-EBITDA only.
HBIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.1  Med: 8.6 Max: 75.9
Current: 42.22
3.1
75.9
Shiller P/E 50.90
HBIO's Shiller P/E is ranked lower than
61% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 44.27 vs. HBIO: 50.90 )
Ranked among companies with meaningful Shiller P/E only.
HBIO' s Shiller P/E Range Over the Past 10 Years
Min: 3.07  Med: 52 Max: 439
Current: 50.9
3.07
439
Current Ratio 3.15
HBIO's Current Ratio is ranked higher than
65% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. HBIO: 3.15 )
Ranked among companies with meaningful Current Ratio only.
HBIO' s Current Ratio Range Over the Past 10 Years
Min: 1.97  Med: 3.93 Max: 11.53
Current: 3.15
1.97
11.53
Quick Ratio 1.66
HBIO's Quick Ratio is ranked higher than
51% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. HBIO: 1.66 )
Ranked among companies with meaningful Quick Ratio only.
HBIO' s Quick Ratio Range Over the Past 10 Years
Min: 1.15  Med: 2.88 Max: 10.71
Current: 1.66
1.15
10.71
Days Inventory 142.20
HBIO's Days Inventory is ranked lower than
60% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.57 vs. HBIO: 142.20 )
Ranked among companies with meaningful Days Inventory only.
HBIO' s Days Inventory Range Over the Past 10 Years
Min: 95  Med: 107.85 Max: 142.2
Current: 142.2
95
142.2
Days Sales Outstanding 55.66
HBIO's Days Sales Outstanding is ranked higher than
61% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.25 vs. HBIO: 55.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
HBIO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.14  Med: 56.58 Max: 64.58
Current: 55.66
47.14
64.58
Days Payable 41.44
HBIO's Days Payable is ranked lower than
59% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 48.01 vs. HBIO: 41.44 )
Ranked among companies with meaningful Days Payable only.
HBIO' s Days Payable Range Over the Past 10 Years
Min: 29.04  Med: 37.92 Max: 53.48
Current: 41.44
29.04
53.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.00
HBIO's 3-Year Average Share Buyback Ratio is ranked lower than
59% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.10 vs. HBIO: -5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HBIO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -75  Med: -0.5 Max: 2.8
Current: -5
-75
2.8

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 10.66
HBIO's Price/Net Current Asset Value is ranked lower than
59% of the 116 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.50 vs. HBIO: 10.66 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
HBIO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.89  Med: 3.79 Max: 20.79
Current: 10.66
1.89
20.79
Price/Tangible Book 6.14
HBIO's Price/Tangible Book is ranked lower than
59% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.58 vs. HBIO: 6.14 )
Ranked among companies with meaningful Price/Tangible Book only.
HBIO' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.65  Med: 3.03 Max: 7.78
Current: 6.14
1.65
7.78
Price/Projected FCF 1.07
HBIO's Price/Projected FCF is ranked higher than
81% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.95 vs. HBIO: 1.07 )
Ranked among companies with meaningful Price/Projected FCF only.
HBIO' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.47  Med: 0.92 Max: 1.54
Current: 1.07
0.47
1.54
Price/Median PS Value 0.81
HBIO's Price/Median PS Value is ranked higher than
80% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.18 vs. HBIO: 0.81 )
Ranked among companies with meaningful Price/Median PS Value only.
HBIO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.64  Med: 1.08 Max: 4.23
Current: 0.81
0.64
4.23
Earnings Yield (Greenblatt) (%) -1.70
HBIO's Earnings Yield (Greenblatt) (%) is ranked lower than
63% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.90 vs. HBIO: -1.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HBIO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.7  Med: 8.1 Max: 22.5
Current: -1.7
-1.7
22.5
Forward Rate of Return (Yacktman) (%) -26.92
HBIO's Forward Rate of Return (Yacktman) (%) is ranked lower than
94% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.20 vs. HBIO: -26.92 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HBIO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -27.5  Med: 7.2 Max: 18.4
Current: -26.92
-27.5
18.4

More Statistics

Revenue (TTM) (Mil) $107.2
EPS (TTM) $ -0.57
Beta0.82
Short Percentage of Float0.93%
52-Week Range $2.41 - 4.28
Shares Outstanding (Mil)34.31

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 108 113 125
EPS ($) 0.15 0.20 0.27
EPS w/o NRI ($) 0.15 0.20 0.27
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for HBIO

Headlines

Articles On GuruFocus.com
Latest Stock Trades from Century Management: Buys POT, HWCC, PICO, AU, KGC Jan 15 2014 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Nov 05 2010 
Weekly CEO Buys Highlight: Saul Centers Inc, Harvard Bioscience Inc, BGC Partners Inc., Chatham Lodg Sep 25 2010 
Weekly CEO Buys Highlight: Saul Centers Inc, Spartech Corp, Harvard Bioscience Inc, Rural/Metro Corp Sep 18 2010 
Harvard Bioscience Inc. Reports Operating Results (10-Q) May 07 2010 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Nov 09 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Aug 10 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q) May 07 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q/A) Feb 19 2009 

More From Other Websites
ETF’s with exposure to Harvard Bioscience, Inc. : September 9, 2016 Sep 09 2016
Harvard Bioscience (HBIO): Moving Average Crossover Alert Aug 29 2016
EXCLUSIVE: UW president lays out vision for Global Innovation Exchange Aug 17 2016
HARVARD BIOSCIENCE INC Financials Aug 13 2016
Harvard Bioscience, Inc. :HBIO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 Aug 11 2016
HARVARD BIOSCIENCE INC Files SEC form 10-Q, Quarterly Report Aug 04 2016
Harvard Bioscience reports 2Q loss Jul 28 2016
Harvard Bioscience reports 2Q loss Jul 28 2016
Harvard Bioscience Inc Earnings Call scheduled for 8:30 am ET today Jul 28 2016
Q2 2016 Harvard Bioscience Inc Earnings Release - Before Market Open Jul 28 2016
HARVARD BIOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 28 2016
Harvard Bioscience Reports Second Quarter 2016 Financial Results Jul 28 2016
Harvard Bioscience Reports Second Quarter 2016 Financial Results Jul 28 2016
ETF’s with exposure to Harvard Bioscience, Inc. : July 21, 2016 Jul 21 2016
Harvard Bioscience Schedules Second Quarter 2016 Conference Call for July 28 at 8:30 AM ET Jul 18 2016
ETF’s with exposure to Harvard Bioscience, Inc. : July 1, 2016 Jul 01 2016
HARVARD BIOSCIENCE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 27 2016
Harvard Bioscience to Attend The Benchmark Company, LLC One-on-One Conference in Milwaukee,... May 31 2016
HARVARD BIOSCIENCE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... May 27 2016
HARVARD BIOSCIENCE INC Files SEC form 10-Q, Quarterly Report May 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)